Feature

Head of Investment at BB Biotech, Daniel Koller, discusses sector growth and the attractive valuations of fast growing companies.

Our video series continues

Bought for €1 by Santander

Many successful funds nearing capacity

Heartwood's Michael Stanes

Risk scenarios vary from country to country

Italy remains a risk

Friendlier regulatory environment expected

Previously warned on pharma dividends

Housebuilders and retailers